Antu Biotech (603658): The 24Q1 profit growth rate exceeded expectations, and the regular business grew steadily
Antu Biotech (603658): Rapid overseas growth, profit levels have increased
Antu Biotech (603658) Review: Regular business growth is steady, new products are being developed at an accelerated pace
Antu Biotech (603658): Regular business is growing steadily, and profit levels are improving
Antu Biotech (603658): The light emitting business will grow steadily in 2023, and profitability will increase steadily
Huaan Securities released a research report on April 22 stating that it gave Antu Biotech (603658.SH) a purchase rating. The main reasons for the rating include: 1) the light emitting business continued to grow steadily, with a growth rate of about 24.88%
Antu Biotech (603658): 1Q24 profit grew rapidly year over year, strong dividends increased shareholder returns
Antu Biotech (603658): Steady growth of multiple production lines and continuous improvement in profitability
Huafu Securities released a research report on April 21 stating that it gave Antu Biotech (603658.SH) a purchase rating, and the target price was 65.48 yuan. The main reasons for the rating include: 1) the company released the 2023 annual report and the 2
Antu Biotech (603658): Steady growth in routine diagnosis and improvement in profitability
Antu Biotech (603658): Strong increase in 24Q1 performance and steady expansion of domestic and foreign markets
Antu Biotech (603658) 2023 Annual Report Review: Excluding the impact of COVID-19, steady growth, and continuous launch of new products
Antu Biotech (603658): 1Q net profit increased year-on-year high, profitability improved
Antu Biotech (603658): Q1 profit exceeded expectations and is optimistic about the potential for subsequent acceleration
Antu Biotech (603658): Continued optimization of revenue structure, first-quarter results greatly exceeded expectations
Antu Biotech (603658): IVD's comprehensive layout makes multiple efforts and strong rise
Antu Biotech (603658): IVD's comprehensive layout makes multiple efforts and strong rise
Antu Biotech (603658): Establishing a benchmark for IVD platformization based on immunosuppression
Antubio (603658): Short-term performance under pressure, steady growth in self-produced business
Antu Biotech (603658): Luminescence business is growing steadily, molecular business is under short-term pressure
No Data